SE9803240D0 - A pharmaceutical composition having a rapid action - Google Patents

A pharmaceutical composition having a rapid action

Info

Publication number
SE9803240D0
SE9803240D0 SE9803240A SE9803240A SE9803240D0 SE 9803240 D0 SE9803240 D0 SE 9803240D0 SE 9803240 A SE9803240 A SE 9803240A SE 9803240 A SE9803240 A SE 9803240A SE 9803240 D0 SE9803240 D0 SE 9803240D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical composition
rapid action
microparticles
bioadhesion
soluble
Prior art date
Application number
SE9803240A
Other languages
English (en)
Swedish (sv)
Inventor
Christer Nystroem
Anders Pettersson
Original Assignee
Diabact Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20412702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9803240(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Diabact Ab filed Critical Diabact Ab
Priority to SE9803240A priority Critical patent/SE9803240D0/xx
Publication of SE9803240D0 publication Critical patent/SE9803240D0/xx
Priority to PT141750851T priority patent/PT2805716T/pt
Priority to CA2629988A priority patent/CA2629988C/en
Priority to HU0800435A priority patent/HU230468B1/hu
Priority to EP05077875.2A priority patent/EP1652518B1/en
Priority to EP99952867A priority patent/EP1115383B1/en
Priority to PCT/SE1999/001687 priority patent/WO2000016750A1/en
Priority to CA2820588A priority patent/CA2820588C/en
Priority to CZ20011029A priority patent/CZ302975B6/cs
Priority to IL14213599A priority patent/IL142135A0/xx
Priority to EP10001408.3A priority patent/EP2236133B1/en
Priority to EP10001406.7A priority patent/EP2236132B1/en
Priority to PL383971A priority patent/PL204264B1/pl
Priority to CA002345121A priority patent/CA2345121C/en
Priority to AT99952867T priority patent/ATE365540T1/de
Priority to SK402-2001A priority patent/SK283302B6/sk
Priority to DK10001406.7T priority patent/DK2236132T3/da
Priority to US09/787,888 priority patent/US6761910B1/en
Priority to PT100014067T priority patent/PT2236132E/pt
Priority to PT99952867T priority patent/PT1115383E/pt
Priority to EEP200700030A priority patent/EE05023B1/xx
Priority to CZ2008-315A priority patent/CZ2008315A3/cs
Priority to NZ510284A priority patent/NZ510284A/en
Priority to ES99952867T priority patent/ES2289829T3/es
Priority to MXPA01003068A priority patent/MXPA01003068A/es
Priority to DK14175085.1T priority patent/DK2805716T3/en
Priority to RU2001111025/14A priority patent/RU2193879C1/ru
Priority to CNB998135453A priority patent/CN1173694C/zh
Priority to KR1020017003715A priority patent/KR100760536B1/ko
Priority to ES10001408.3T priority patent/ES2498095T3/es
Priority to PL347126A priority patent/PL201644B1/pl
Priority to AU64927/99A priority patent/AU764346B2/en
Priority to DK10001408.3T priority patent/DK2236133T3/da
Priority to BRPI9913945A priority patent/BRPI9913945B8/pt
Priority to ES14175085.1T priority patent/ES2644770T3/es
Priority to ES05077875T priority patent/ES2433930T3/es
Priority to DK99952867T priority patent/DK1115383T3/da
Priority to JP2000573711A priority patent/JP3381220B2/ja
Priority to PT50778752T priority patent/PT1652518E/pt
Priority to EEP200800028A priority patent/EE05555B1/xx
Priority to PT100014083T priority patent/PT2236133E/pt
Priority to EP14175085.1A priority patent/EP2805716B1/en
Priority to EEP200100182A priority patent/EE04927B1/xx
Priority to TR2001/00855T priority patent/TR200100855T2/xx
Priority to DE69936393T priority patent/DE69936393T2/de
Priority to DK05077875.2T priority patent/DK1652518T3/da
Priority to HU0103856A priority patent/HU230342B1/hu
Priority to ES10001406.7T priority patent/ES2507579T3/es
Priority to NO20011473A priority patent/NO332226B1/no
Priority to BG105379A priority patent/BG65502B1/bg
Priority to US10/851,215 priority patent/US20040213855A1/en
Priority to US11/544,660 priority patent/US7910132B2/en
Priority to HK11102567.6A priority patent/HK1148457A1/xx
Priority to HK11102568.5A priority patent/HK1148458A1/xx
Priority to HK06111773.4A priority patent/HK1091722A1/xx
Priority to CY20071101054T priority patent/CY1107711T1/el
Priority to US12/216,197 priority patent/US20080286368A1/en
Priority to US13/302,720 priority patent/US8512747B2/en
Priority to US13/302,694 priority patent/US8454996B2/en
Priority to US13/799,640 priority patent/US20130195976A1/en
Priority to US13/954,141 priority patent/US20140030336A1/en
Priority to CY20131100974T priority patent/CY1114620T1/el
Priority to CY20141100588T priority patent/CY1115685T1/el
Priority to CY20141100730T priority patent/CY1115688T1/el
Priority to LU92636C priority patent/LU92636I2/xx
Priority to HK15103632.1A priority patent/HK1203144A1/xx
Priority to CY20171101261T priority patent/CY1119644T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
SE9803240A 1998-09-24 1998-09-24 A pharmaceutical composition having a rapid action SE9803240D0 (sv)

Priority Applications (67)

Application Number Priority Date Filing Date Title
SE9803240A SE9803240D0 (sv) 1998-09-24 1998-09-24 A pharmaceutical composition having a rapid action
PT141750851T PT2805716T (pt) 1998-09-24 1999-09-24 Composição farmacêutica compreendendo buprenorfina possuindo uma ação rápida
CA2629988A CA2629988C (en) 1998-09-24 1999-09-24 Pharmaceutical composition for the treatment of acute disorders
HU0800435A HU230468B1 (hu) 1998-09-24 1999-09-24 Gyógyszerkészítmény álmatlanság kezelésére
EP05077875.2A EP1652518B1 (en) 1998-09-24 1999-09-24 Pharmaceutical composition for sublingual administration
EP99952867A EP1115383B1 (en) 1998-09-24 1999-09-24 Treatment of acute disorders by sublingual administration of a pharmaceutical composition
PCT/SE1999/001687 WO2000016750A1 (en) 1998-09-24 1999-09-24 Pharmaceutical composition for the treatment of acute disorders
CA2820588A CA2820588C (en) 1998-09-24 1999-09-24 Pharmaceutical composition for the treatment of acute disorders
CZ20011029A CZ302975B6 (cs) 1998-09-24 1999-09-24 Farmaceutický prípravek pro ošetrení akutních potíží pro podání pod jazyk
IL14213599A IL142135A0 (en) 1998-09-24 1999-09-24 Pharmaceutical composition for the treatment of acute disorders
EP10001408.3A EP2236133B1 (en) 1998-09-24 1999-09-24 Pharmaceutical composition comprising fentanyl for the treatment of acute or breakthrough pain by sublingual administration
EP10001406.7A EP2236132B1 (en) 1998-09-24 1999-09-24 Pharmaceutical composition for the treatment of insomnia by sublingual administration
PL383971A PL204264B1 (pl) 1998-09-24 1999-09-24 Bioadhezyjna i/lub mukoadhezyjna kompozycja farmaceutyczna
CA002345121A CA2345121C (en) 1998-09-24 1999-09-24 Pharmaceutical composition for the treatment of acute disorders
AT99952867T ATE365540T1 (de) 1998-09-24 1999-09-24 Behandlung akuter gesundheitsstörungen durch die sublingual verabreichung einer pharmazeutischen zusammensetzung
SK402-2001A SK283302B6 (sk) 1998-09-24 1999-09-24 Farmaceutický prostriedok na liečenie akútnych stavov a jeho použitie
DK10001406.7T DK2236132T3 (da) 1998-09-24 1999-09-24 Farmaceutisk sammensætning til behandlingen af søvnløshed ved sublingual administration
US09/787,888 US6761910B1 (en) 1998-09-24 1999-09-24 Pharmaceutical composition for the treatment of acute disorders
PT100014067T PT2236132E (pt) 1998-09-24 1999-09-24 Composição farmacêutica para o tratamento da insónia por administração sublingual
PT99952867T PT1115383E (pt) 1998-09-24 1999-09-24 Tratamento de perturbações agudas por administração sublingual de uma composição farmacêutica.
EEP200700030A EE05023B1 (et) 1998-09-24 1999-09-24 Fentanli kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud akuutse valu raviks, ning farmatseutiline kompositsioon
CZ2008-315A CZ2008315A3 (cs) 1998-09-24 1999-09-24 Farmaceutický přípravek pro léčení potíží s nespavostí ve formě pro podání pod jazyk
NZ510284A NZ510284A (en) 1998-09-24 1999-09-24 A solid form dosage for sublingual administration of medicaments for treating acute disorders such as pain
ES99952867T ES2289829T3 (es) 1998-09-24 1999-09-24 Tratamiento de desordenes agudos por administracion sublingual de una composicion farmaceutica.
MXPA01003068A MXPA01003068A (es) 1998-09-24 1999-09-24 Composicion farmaceutica para el tratamiento de alteraciones agudas.
DK14175085.1T DK2805716T3 (en) 1998-09-24 1999-09-24 Pharmaceutical composition comprising buprenorphine with rapid action
RU2001111025/14A RU2193879C1 (ru) 1998-09-24 1999-09-24 Фармацевтическая композиция для лечения острых нарушений
CNB998135453A CN1173694C (zh) 1998-09-24 1999-09-24 用于治疗急性疾病的药用组合物
KR1020017003715A KR100760536B1 (ko) 1998-09-24 1999-09-24 급성 장해 치료용 약제학적 조성물
ES10001408.3T ES2498095T3 (es) 1998-09-24 1999-09-24 Composición farmacéutica que comprende fentanil para el tratamiento del cáncer o el dolor intercurrente o agudo mediante administración sublingual
PL347126A PL201644B1 (pl) 1998-09-24 1999-09-24 Zastosowanie kompozycji farmaceutycznej do leczenia ostrych zaburzeń
AU64927/99A AU764346B2 (en) 1998-09-24 1999-09-24 Pharmaceutical composition for the treatment of acute disorders
DK10001408.3T DK2236133T3 (da) 1998-09-24 1999-09-24 Farmaceutisk sammensætning omfattende fentanyl til behandlingen af akut- eller gennembrydningssmerte ved sublingual administration
BRPI9913945A BRPI9913945B8 (pt) 1998-09-24 1999-09-24 Composição farmacêutica rapidamente atuante para a administração sublingual de um agente farmacêutico para o tratamento de distúrbios agudos
ES14175085.1T ES2644770T3 (es) 1998-09-24 1999-09-24 Una composición farmacéutica que comprende buprenorfina que tiene una acción rápida
ES05077875T ES2433930T3 (es) 1998-09-24 1999-09-24 Composición farmacéutica para administración sublingual
DK99952867T DK1115383T3 (da) 1998-09-24 1999-09-24 Behandling af akutte lidelser ved sublingual indgivelse af at farmaceutisk præparat
JP2000573711A JP3381220B2 (ja) 1998-09-24 1999-09-24 急性疾患の処置のための製薬学的組成物
PT50778752T PT1652518E (pt) 1998-09-24 1999-09-24 ¿composição farmacêutica para administração sublingual
EEP200800028A EE05555B1 (et) 1998-09-24 1999-09-24 Farmatseutiline kompositsioon ja selle kasutamine ravimi valmistamiseks, mis on ette n„htud insomnia ravimiseks
PT100014083T PT2236133E (pt) 1998-09-24 1999-09-24 Composição farmacêutica que compreende fentanilo para o tratamento de dor aguda e repentina por administração sublingual
EP14175085.1A EP2805716B1 (en) 1998-09-24 1999-09-24 A pharmaceutical composition comprising buprenorphine having a rapid action
EEP200100182A EE04927B1 (et) 1998-09-24 1999-09-24 Farmatseutiline kompositsioon ja selle kasutamineravimi valmistamiseks, mis on ette n„htud akuutsete h„irete raviks
TR2001/00855T TR200100855T2 (tr) 1998-09-24 1999-09-24 Akut bozuklukların tedavisi için farmasötik komposizyon
DE69936393T DE69936393T2 (de) 1998-09-24 1999-09-24 Behandlung akuter gesundheitsstörungen durch die sublingual verabreichung einer pharmazeutischen zusammensetzung
DK05077875.2T DK1652518T3 (da) 1998-09-24 1999-09-24 Farmaceutisk sammensætning til sublingval administration
HU0103856A HU230342B1 (hu) 1998-09-24 1999-09-24 Gyógyszerkészítmény akut rendellenességek kezelésére
ES10001406.7T ES2507579T3 (es) 1998-09-24 1999-09-24 Composición farmacéutica para el tratamiento del insomnio mediante administración sublingual
NO20011473A NO332226B1 (no) 1998-09-24 2001-03-22 Farmasoytisk preparat for behandling av akutte lidelser ved sublingval administrering samt anvendelse av minst en doseringsenhet av en i det vesentlige vannfri farmasoytisk sammensetning
BG105379A BG65502B1 (bg) 1998-09-24 2001-03-23 Фармацевтичен състав за лечение на остри неразположения и неговото използване
US10/851,215 US20040213855A1 (en) 1998-09-24 2004-05-24 Pharmaceutical composition for the treatment of acute disorders
US11/544,660 US7910132B2 (en) 1998-09-24 2006-10-10 Pharmaceutical composition for the treatment of acute disorders
HK11102567.6A HK1148457A1 (en) 1998-09-24 2006-10-25 Pharmaceutical composition for the treatment of insomnia by sublingual administration
HK11102568.5A HK1148458A1 (en) 1998-09-24 2006-10-25 Pharmaceutical composition comprising fentanyl for the treatment of acute or breakthrough pain by sublingual administration
HK06111773.4A HK1091722A1 (en) 1998-09-24 2006-10-25 Pharmaceutical composition for sublingual administration
CY20071101054T CY1107711T1 (el) 1998-09-24 2007-08-07 Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων
US12/216,197 US20080286368A1 (en) 1998-09-24 2008-07-01 Pharmaceutical composition for the treatment of acute disorders
US13/302,720 US8512747B2 (en) 1998-09-24 2011-11-22 Pharmaceutical composition for the treatment of acute disorders
US13/302,694 US8454996B2 (en) 1998-09-24 2011-11-22 Pharmaceutical composition for the treatment of acute disorders
US13/799,640 US20130195976A1 (en) 1998-09-24 2013-03-13 Pharmaceutical composition for the treatment of acute disorders
US13/954,141 US20140030336A1 (en) 1998-09-24 2013-07-30 Pharmaceutical composition for the treatment of acute disorders
CY20131100974T CY1114620T1 (el) 1998-09-24 2013-11-04 Φαρμακευτικη συνθεση προς υπογλωσσια χορηγηση
CY20141100588T CY1115685T1 (el) 1998-09-24 2014-08-04 Φαρμακευτικη συνθεση προς αγωγη εναντι αϋπνιας μεσω υπογλωσσιας χορηγησης
CY20141100730T CY1115688T1 (el) 1998-09-24 2014-09-10 Φαρμακευτικη συνθεση που περιλαμβανει φεντανυλη προς αγωγη εναντι οξεος ή παροξυσμικου πονου μεσω υπογλωσσιας χορηγησης
LU92636C LU92636I2 (fr) 1998-09-24 2015-01-20 Zolpidem et ses sels pharmaceutiquement acceptables
HK15103632.1A HK1203144A1 (en) 1998-09-24 2015-04-14 A pharmaceutical composition having a rapid action
CY20171101261T CY1119644T1 (el) 1998-09-24 2017-11-30 Φαρμακευτικη συνθεση ταχειας δρασης που περιλαμβανει βουπρενορφινη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9803240A SE9803240D0 (sv) 1998-09-24 1998-09-24 A pharmaceutical composition having a rapid action

Publications (1)

Publication Number Publication Date
SE9803240D0 true SE9803240D0 (sv) 1998-09-24

Family

ID=20412702

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9803240A SE9803240D0 (sv) 1998-09-24 1998-09-24 A pharmaceutical composition having a rapid action

Country Status (30)

Country Link
US (8) US6761910B1 (cs)
EP (5) EP1115383B1 (cs)
JP (1) JP3381220B2 (cs)
KR (1) KR100760536B1 (cs)
CN (1) CN1173694C (cs)
AT (1) ATE365540T1 (cs)
AU (1) AU764346B2 (cs)
BG (1) BG65502B1 (cs)
BR (1) BRPI9913945B8 (cs)
CA (3) CA2629988C (cs)
CY (5) CY1107711T1 (cs)
CZ (2) CZ2008315A3 (cs)
DE (1) DE69936393T2 (cs)
DK (5) DK2236132T3 (cs)
EE (3) EE04927B1 (cs)
ES (5) ES2644770T3 (cs)
HK (4) HK1148457A1 (cs)
HU (2) HU230342B1 (cs)
IL (1) IL142135A0 (cs)
LU (1) LU92636I2 (cs)
MX (1) MXPA01003068A (cs)
NO (1) NO332226B1 (cs)
NZ (1) NZ510284A (cs)
PL (2) PL204264B1 (cs)
PT (5) PT2805716T (cs)
RU (1) RU2193879C1 (cs)
SE (1) SE9803240D0 (cs)
SK (1) SK283302B6 (cs)
TR (1) TR200100855T2 (cs)
WO (1) WO2000016750A1 (cs)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
DK1642578T3 (da) 2000-07-31 2013-08-12 Takeda Pharma As Fentanyl salt-sammensætning til nasal administration
AU2002221939A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Rapidly disintegrating tablet comprising an acid-labile active ingredient
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
EP1469839A2 (en) * 2002-01-25 2004-10-27 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
CA2480377A1 (en) * 2002-03-26 2003-10-09 Teva Pharmaceutical Industries Ltd. Drug microparticles
ES2199061B1 (es) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
AU2003299659A1 (en) 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20060216352A1 (en) * 2003-01-31 2006-09-28 Orexo Ab Rapid-acting pharmaceutical composition
ITRM20030288A1 (it) * 2003-06-10 2004-12-11 Valerio Cioli Somministrazione sublinguale di antinfiammatori non steroidei (fans)
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
BRPI0418228B8 (pt) * 2003-12-31 2021-05-25 Cima Labs Inc forma de dosagem, e, método de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
AU2004311879B2 (en) * 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US7658945B2 (en) * 2004-02-17 2010-02-09 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US8163114B2 (en) * 2004-04-07 2012-04-24 New Jersey Institute Of Technology Netshape manufacturing processes and compositions
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
SI1758590T1 (sl) * 2004-05-19 2012-03-30 Los Angeles Biomed Res Inst Uporaba detergenta za nekirurško odstranitev maščobe
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
GB0423800D0 (en) * 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
MX2007008575A (es) * 2005-01-14 2007-09-07 Cima Labs Inc Empaque vesicular resistente a ninos, no rasgable.
ES2375974T3 (es) * 2005-01-14 2012-03-07 Cima Labs Inc. Envase de pastillas del tipo de doblar y despegar.
JP2008530070A (ja) * 2005-02-10 2008-08-07 オレクソ・アクチエボラゲット 薬物の経粘膜投与に有用な新規な医薬組成物
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
CA2599386A1 (en) * 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of pain
CN101141949B (zh) * 2005-03-28 2010-12-08 奥瑞克索股份公司 用于治疗帕金森病的药物组合物
US20090232898A1 (en) * 2005-03-28 2009-09-17 Anders Pettersson Pharmaceutical Compositions Useful in the Treatment of Migraine
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
NZ563979A (en) * 2005-05-25 2011-02-25 Transcept Pharmaceuticals Inc Solid compositions and methods for treating middle-of-the night insomnia
CN101198327B (zh) * 2005-05-25 2012-06-20 特兰斯塞普特制药公司 治疗半夜失眠的固体组合物和方法
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
CN101378735B (zh) * 2006-01-25 2013-04-03 英西斯治疗学股份有限公司 芬太尼舌下喷雾剂
US20080057129A1 (en) * 2006-04-03 2008-03-06 Lerner E I Drug microparticles
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
EP2037895A4 (en) * 2006-05-23 2009-12-02 Orahealth Corp XYLITOL-PASTILLAS AND METHOD OF USE
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
ITMI20061117A1 (it) * 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US8470361B2 (en) 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
US20110077200A1 (en) * 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
US20100041689A1 (en) 2006-12-19 2010-02-18 University Of Virginia Patent Foundation Combined Effects of Topiramate and Ondansetron on Alcohol Consumption
DE102007010109A1 (de) * 2007-02-28 2008-09-04 Henkel Ag & Co. Kgaa Wirkstoffträgersysteme
US9339463B2 (en) * 2007-12-06 2016-05-17 Michael Zamloot Micronized opioid compositions having a specific particle size distribution
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
EP2254558B1 (en) * 2008-02-05 2019-03-13 Alpex Pharma SA Orally disintegrating tablets with speckled appearance
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
EP2111857A1 (de) * 2008-04-25 2009-10-28 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
SE533540C2 (sv) 2008-12-19 2010-10-19 Neoinvent Medical Engineering Ab Administrerinssystem för administrering av en substans i munhålan
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
JP5702526B2 (ja) 2009-04-30 2015-04-15 Ｅｓファイバービジョンズ株式会社 抗ウイルス性を有する硫酸化セルロースを担持させた繊維集合体
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
NO2493457T3 (cs) 2009-10-30 2018-01-06
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
IL278149B2 (en) 2010-07-02 2024-03-01 Univ Virginia Patent Foundation A molecular genetic approach to the treatment and diagnosis of alcohol and drug dependence
ITMI20101426A1 (it) * 2010-07-29 2012-01-30 Altergon Sa Composizione contenente condroitin solfato
FR2967066B1 (fr) * 2010-11-04 2013-06-14 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes
WO2012106058A2 (en) * 2011-01-31 2012-08-09 New Market Pharmaceuticals Animal treatments
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
BR112013028890A2 (pt) 2011-05-09 2017-01-31 Univ Virginia Patent Foundation composições e métodos para o tratamento de câncer
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
PT2706986E (pt) 2011-09-19 2015-07-07 Orexo Ab Nova composição farmacêutica resistente ao abuso para o tratamento da dependência de opiáceos
TR201815935T4 (tr) 2012-05-02 2018-11-21 Orexo Ab Akut ağrının tedavisi için yeni alfentanil bileşimi.
RU2673818C2 (ru) 2012-11-30 2018-11-30 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US20160296463A1 (en) 2013-11-11 2016-10-13 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods thereof
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
JP2017519803A (ja) 2014-07-08 2017-07-20 インシス・ファーマ・インコーポレーテッド 舌下ナロキソンスプレー
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
MY187877A (en) 2014-12-23 2021-10-26 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN108697803A (zh) * 2015-10-29 2018-10-23 索卢贝斯特有限公司 透粘膜给药的药物组合物
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CN107157994A (zh) * 2017-06-09 2017-09-15 董鹏 一种托拉塞米的舌下口服制剂

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
US4229447A (en) * 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4432975A (en) * 1981-04-13 1984-02-21 Icn Pharmaceuticals, Inc. Process for introducing vitamin B-12 into the bloodstream
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
GB8522453D0 (en) * 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
DE3715682A1 (de) * 1987-05-11 1988-11-24 Stefan Dr Lueth Vorrichtung zum herstellen eines zweikomponentengemisches
SE8800080L (sv) * 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
SE8803935L (sv) * 1988-10-31 1990-05-01 Kabivitrum Ab Laekemedelskomposition
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
IE66203B1 (en) * 1989-12-04 1995-12-13 Searle & Co System for transdermal albuterol administration
US5370862A (en) * 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
FR2694194B1 (fr) 1992-07-31 1994-11-04 Health Business Dev Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel.
JPH0665103A (ja) 1992-08-13 1994-03-08 ▲寛▼治 ▲高▼田 向精神薬のための速吸収性舌下投与製剤
JPH08504189A (ja) 1992-09-21 1996-05-07 キン、ボーイ 低／非たんでき性オピオイド鎮痛剤の確認及び使用方法
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
DE19652268C2 (de) 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
DE19652188C2 (de) 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19758564A1 (de) * 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
KR100289471B1 (ko) * 1998-01-19 2001-09-17 김충섭 휀타닐계마취제의이식형서방성제제
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6264974B1 (en) * 1998-07-07 2001-07-24 Salvagnini Italia Spa Buccal and sublingual administration of physostigmine
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
WO2001030391A2 (en) 1999-10-27 2001-05-03 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
CN1290525A (zh) 2000-10-10 2001-04-11 北京万全阳光医药科技有限公司 冷冻干燥的扎来普隆速溶口服组合物
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
MXPA04006779A (es) 2002-01-10 2005-04-25 Biovail Lab Inc Formulaciones de sedantes no benzodiazepinicos.
CN1418631A (zh) 2002-12-19 2003-05-21 王登之 治疗失眠的佐匹克隆口腔崩解片及其制备方法
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets

Also Published As

Publication number Publication date
CA2629988A1 (en) 2000-03-30
EP2236132B1 (en) 2014-07-23
PT1115383E (pt) 2007-07-13
CY1114620T1 (el) 2016-10-05
BR9913945A (pt) 2001-06-12
CY1119644T1 (el) 2018-04-04
EP1652518B1 (en) 2013-08-07
CZ306387B6 (cs) 2016-12-28
CA2820588A1 (en) 2000-03-30
TR200100855T2 (tr) 2001-10-22
EP2236132A1 (en) 2010-10-06
HU230342B1 (hu) 2016-02-29
CA2820588C (en) 2015-11-17
DE69936393D1 (de) 2007-08-09
EP2236133B1 (en) 2014-07-02
CZ302975B6 (cs) 2012-02-01
DK2236133T3 (da) 2014-07-14
SK4022001A3 (en) 2001-11-06
HK1148458A1 (en) 2011-09-09
NO20011473D0 (no) 2001-03-22
EP1652518A1 (en) 2006-05-03
WO2000016750A1 (en) 2000-03-30
PT2236132E (pt) 2014-07-31
MXPA01003068A (es) 2004-09-13
ES2498095T3 (es) 2014-09-24
HUP0103856A2 (hu) 2002-02-28
US20070031502A1 (en) 2007-02-08
HK1203144A1 (en) 2015-10-23
PT2805716T (pt) 2017-12-21
DE69936393T2 (de) 2008-03-13
CN1173694C (zh) 2004-11-03
ES2289829T3 (es) 2008-02-01
DK1115383T3 (da) 2007-07-30
ES2507579T3 (es) 2014-10-15
AU764346B2 (en) 2003-08-14
CZ2008315A3 (cs) 2016-12-28
JP2002526439A (ja) 2002-08-20
CZ20011029A3 (cs) 2001-08-15
EP2236133A1 (en) 2010-10-06
CA2629988C (en) 2014-01-07
BG65502B1 (bg) 2008-10-31
DK2236132T3 (da) 2014-08-04
KR100760536B1 (ko) 2007-10-04
CY1107711T1 (el) 2013-04-18
ES2644770T3 (es) 2017-11-30
PL347126A1 (en) 2002-03-25
HU0800435D0 (en) 2008-09-29
HK1148457A1 (en) 2011-09-09
EE04927B1 (et) 2007-12-17
ES2433930T3 (es) 2013-12-13
AU6492799A (en) 2000-04-10
NO20011473L (no) 2001-05-23
BG105379A (en) 2001-12-29
US20080286368A1 (en) 2008-11-20
SK283302B6 (sk) 2003-05-02
US20140030336A1 (en) 2014-01-30
HK1091722A1 (en) 2007-01-26
ATE365540T1 (de) 2007-07-15
EE05555B1 (et) 2012-08-15
US7910132B2 (en) 2011-03-22
EP2805716B1 (en) 2017-09-13
EP1115383A1 (en) 2001-07-18
LU92636I2 (fr) 2015-03-20
US20040213855A1 (en) 2004-10-28
CA2345121A1 (en) 2000-03-30
PT1652518E (pt) 2013-10-01
NZ510284A (en) 2003-05-30
DK1652518T3 (da) 2013-10-28
EP2805716A1 (en) 2014-11-26
US8512747B2 (en) 2013-08-20
CN1326340A (zh) 2001-12-12
PL204264B1 (pl) 2009-12-31
CA2345121C (en) 2008-06-10
BR9913945B1 (pt) 2017-10-24
US20120315331A1 (en) 2012-12-13
PT2236133E (pt) 2014-07-16
BRPI9913945B8 (pt) 2022-01-25
CY1115685T1 (el) 2017-01-25
HUP0103856A3 (en) 2003-11-28
EE200700030A (et) 2007-08-15
US20130195976A1 (en) 2013-08-01
KR20010075315A (ko) 2001-08-09
RU2001111025A (ru) 2004-02-20
PL201644B1 (pl) 2009-04-30
EP1115383B1 (en) 2007-06-27
EE200100182A (et) 2002-08-15
IL142135A0 (en) 2002-03-10
RU2193879C1 (ru) 2002-12-10
DK2805716T3 (en) 2017-10-16
US20120315330A1 (en) 2012-12-13
NO332226B1 (no) 2012-07-30
CY1115688T1 (el) 2017-01-25
US6761910B1 (en) 2004-07-13
JP3381220B2 (ja) 2003-02-24
HU230468B1 (hu) 2016-07-28
EE200800028A (et) 2008-08-15
EE05023B1 (et) 2008-06-16
US8454996B2 (en) 2013-06-04

Similar Documents

Publication Publication Date Title
SE9803240D0 (sv) A pharmaceutical composition having a rapid action
DK1115384T3 (da) Fentanyl-præparat til behandling af akutte smerter
ATE329594T1 (de) Schnell wirkende pharmazeutische zusammensetzung
IL169984A0 (en) A mucoadhesive composition and a process for the preparation thereof
ID27457A (id) Komposisi untuk pengobatan hiv dan infeksi virus lainnya
DK1231890T3 (da) Oralt rensende produkt
ATE275928T1 (de) Zahnpasta